The main focus of the research group is in translational research in gynaecological cancers. In particular biomarker discovery and development (specifically immunological markers) in ovarian and endometrial cancers. The biomarkers are now in the process of being tested for diagnosis and surgical prognosis. The concept of predicting surgical outcome in ovarian cancer is a step in developing personalised medicine and providing patients with best care possible.
Recent advances in oncolgy have improved survival in patients with cancer but research into surgery may have additional benefits for the patient. Clinical research into optimal treatment of cervival preinvasive lesions has been a focus. We have shown that clear margins of resection has a significant effect on reducing risk of recurrence from preinvasive disease.
et al., 2021, Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer., N Engl J Med, Vol:385, Pages:2123-2131
et al., 2021, British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic, International Journal of Gynecological Cancer, ISSN:1048-891X
et al., 2021, COVID-19 and the impact on gynecologic cancer care, International Journal of Gynecology & Obstetrics, Vol:155, ISSN:0020-7292, Pages:94-101
et al., 2021, Diagnostic accuracy of FEC-PET/CT, FDG-PET/CT and diffusion-weighted MRI in detection of nodal metastases in surgically treated endometrial and cervical carcinoma, Clinical Cancer Research, Vol:27, ISSN:1078-0432, Pages:6457-6466
et al., 2021, A novel application of calcium electroporation to cutaneous manifestations of gynaecological cancer, European Journal of Gynecological Oncology, Vol:42, ISSN:0392-2936, Pages:662-672